Discrimination of pancreato-biliary cancer and pancreatitis patients by non-invasive liquid biopsy

Hartwig C, Müller J, Klett H, Kouhestani D, Mittelstädt A, Anthuber A, David P, Brunner M, Jacobsen A, Glanz K, Swierzy I, Roßdeutsch L, Klösch B, Grützmann R, Wittenberger T, Sohn K, Weber G (2024)


Publication Type: Journal article

Publication year: 2024

Journal

Book Volume: 23

Journal Issue: 1

DOI: 10.1186/s12943-024-01943-x

Abstract

Background: Current diagnostics for the detection of pancreato-biliary cancers (PBCs) need to be optimized. We therefore propose that methylated cell-free DNA (cfDNA) derived from non-invasive liquid biopsies serves as a novel biomarker with the ability to discriminate pancreato-biliary cancers from non-cancer pancreatitis patients. Methods: Differentially methylated regions (DMRs) from plasma cfDNA between PBCs, pancreatitis and clinical control samples conditions were identified by next-generation sequencing after enrichment using methyl-binding domains and database searches to generate a discriminatory panel for a hybridization and capture assay with subsequent targeted high throughput sequencing. Results: The hybridization and capture panel, covering around 74 kb in total, was applied to sequence a cohort of 25 PBCs, 25 pancreatitis patients, 25 clinical controls, and seven cases of Intraductal Papillary Mucinous Neoplasia (IPMN). An unbiased machine learning approach identified the 50 most discriminatory methylation markers for the discrimination of PBC from pancreatitis and controls resulting in an AUROC of 0.85 and 0.88 for a training (n = 45) and a validation (n = 37) data set, respectively. The panel was also able to distinguish high grade from low grade IPMN samples. Conclusions: We present a proof of concept for a methylation biomarker panel with better performance and improved discriminatory power than the current clinical marker CA19-9 for the discrimination of pancreato-biliary cancers from non-cancerous pancreatitis patients and clinical controls. This workflow might be used in future diagnostics for the detection of precancerous lesions, e.g. the identification of high grade IPMNs vs. low grade IPMNs.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Hartwig, C., Müller, J., Klett, H., Kouhestani, D., Mittelstädt, A., Anthuber, A.,... Weber, G. (2024). Discrimination of pancreato-biliary cancer and pancreatitis patients by non-invasive liquid biopsy. Molecular Cancer, 23(1). https://doi.org/10.1186/s12943-024-01943-x

MLA:

Hartwig, Christina, et al. "Discrimination of pancreato-biliary cancer and pancreatitis patients by non-invasive liquid biopsy." Molecular Cancer 23.1 (2024).

BibTeX: Download